trial · primary record
Felzartamab
Antibody-mediated Rejection
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 201 |
| Primary completion | 2031-12-31 |
| Primary endpoint | Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI) |
| Registry ID | NCT07444489 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:45.283Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07444489
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Felzartamab · compound